Enterobacteriaceae Infection Drug Market - Global Outlook and Forecast 2024-2031

Report ID: 1377112 | Published Date: Jan 2025 | No. of Page: 60 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Enterobacteriaceae Infection Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Enterobacteriaceae Infection Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Enterobacteriaceae Infection Drug Overall Market Size
    2.1 Global Enterobacteriaceae Infection Drug Market Size: 2021 VS 2028
    2.2 Global Enterobacteriaceae Infection Drug Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Enterobacteriaceae Infection Drug Players in Global Market
    3.2 Top Global Enterobacteriaceae Infection Drug Companies Ranked by Revenue
    3.3 Global Enterobacteriaceae Infection Drug Revenue by Companies
    3.4 Top 3 and Top 5 Enterobacteriaceae Infection Drug Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Enterobacteriaceae Infection Drug Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Enterobacteriaceae Infection Drug Players in Global Market
        3.6.1 List of Global Tier 1 Enterobacteriaceae Infection Drug Companies
        3.6.2 List of Global Tier 2 and Tier 3 Enterobacteriaceae Infection Drug Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Enterobacteriaceae Infection Drug Market Size Markets, 2021 & 2028
        4.1.2 Beta-lactams Drugs
        4.1.3 Carbapenems Drugs
        4.1.4 Fluoroquinolones Drugs
        4.1.5 Others
    4.2 By Type - Global Enterobacteriaceae Infection Drug Revenue & Forecasts
        4.2.1 By Type - Global Enterobacteriaceae Infection Drug Revenue, 2017-2022
        4.2.2 By Type - Global Enterobacteriaceae Infection Drug Revenue, 2023-2028
        4.2.3 By Type - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Enterobacteriaceae Infection Drug Market Size, 2021 & 2028
        5.1.2 Hospital Pharmacies
        5.1.3 Retail Pharmacies
        5.1.4 Online Pharmacies
    5.2 By Application - Global Enterobacteriaceae Infection Drug Revenue & Forecasts
        5.2.1 By Application - Global Enterobacteriaceae Infection Drug Revenue, 2017-2022
        5.2.2 By Application - Global Enterobacteriaceae Infection Drug Revenue, 2023-2028
        5.2.3 By Application - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Enterobacteriaceae Infection Drug Market Size, 2021 & 2028
    6.2 By Region - Global Enterobacteriaceae Infection Drug Revenue & Forecasts
        6.2.1 By Region - Global Enterobacteriaceae Infection Drug Revenue, 2017-2022
        6.2.2 By Region - Global Enterobacteriaceae Infection Drug Revenue, 2023-2028
        6.2.3 By Region - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Enterobacteriaceae Infection Drug Revenue, 2017-2028
        6.3.2 US Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.3.3 Canada Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.3.4 Mexico Enterobacteriaceae Infection Drug Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Enterobacteriaceae Infection Drug Revenue, 2017-2028
        6.4.2 Germany Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.4.3 France Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.4.4 U.K. Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.4.5 Italy Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.4.6 Russia Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.4.7 Nordic Countries Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.4.8 Benelux Enterobacteriaceae Infection Drug Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Enterobacteriaceae Infection Drug Revenue, 2017-2028
        6.5.2 China Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.5.3 Japan Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.5.4 South Korea Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.5.5 Southeast Asia Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.5.6 India Enterobacteriaceae Infection Drug Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Enterobacteriaceae Infection Drug Revenue, 2017-2028
        6.6.2 Brazil Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.6.3 Argentina Enterobacteriaceae Infection Drug Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue, 2017-2028
        6.7.2 Turkey Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.7.3 Israel Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.7.4 Saudi Arabia Enterobacteriaceae Infection Drug Market Size, 2017-2028
        6.7.5 UAE Enterobacteriaceae Infection Drug Market Size, 2017-2028
7 Players Profiles
    7.1 Genentech
        7.1.1 Genentech Corporate Summary
        7.1.2 Genentech Business Overview
        7.1.3 Genentech Enterobacteriaceae Infection Drug Major Product Offerings
        7.1.4 Genentech Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.1.5 Genentech Key News
    7.2 Nanotherapeutics
        7.2.1 Nanotherapeutics Corporate Summary
        7.2.2 Nanotherapeutics Business Overview
        7.2.3 Nanotherapeutics Enterobacteriaceae Infection Drug Major Product Offerings
        7.2.4 Nanotherapeutics Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.2.5 Nanotherapeutics Key News
    7.3 Novartis
        7.3.1 Novartis Corporate Summary
        7.3.2 Novartis Business Overview
        7.3.3 Novartis Enterobacteriaceae Infection Drug Major Product Offerings
        7.3.4 Novartis Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.3.5 Novartis Key News
    7.4 Pfizer
        7.4.1 Pfizer Corporate Summary
        7.4.2 Pfizer Business Overview
        7.4.3 Pfizer Enterobacteriaceae Infection Drug Major Product Offerings
        7.4.4 Pfizer Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.4.5 Pfizer Key News
    7.5 Nymox Pharmaceutical
        7.5.1 Nymox Pharmaceutical Corporate Summary
        7.5.2 Nymox Pharmaceutical Business Overview
        7.5.3 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Major Product Offerings
        7.5.4 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.5.5 Nymox Pharmaceutical Key News
    7.6 Sequoia Sciences
        7.6.1 Sequoia Sciences Corporate Summary
        7.6.2 Sequoia Sciences Business Overview
        7.6.3 Sequoia Sciences Enterobacteriaceae Infection Drug Major Product Offerings
        7.6.4 Sequoia Sciences Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.6.5 Sequoia Sciences Key News
    7.7 Phico Therapeutics
        7.7.1 Phico Therapeutics Corporate Summary
        7.7.2 Phico Therapeutics Business Overview
        7.7.3 Phico Therapeutics Enterobacteriaceae Infection Drug Major Product Offerings
        7.7.4 Phico Therapeutics Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.7.5 Phico Therapeutics Key News
    7.8 Cantab Biopharmaceuticals
        7.8.1 Cantab Biopharmaceuticals Corporate Summary
        7.8.2 Cantab Biopharmaceuticals Business Overview
        7.8.3 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Major Product Offerings
        7.8.4 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
        7.8.5 Cantab Biopharmaceuticals Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Enterobacteriaceae Infection Drug Market Opportunities & Trends in Global Market
    Table 2. Enterobacteriaceae Infection Drug Market Drivers in Global Market
    Table 3. Enterobacteriaceae Infection Drug Market Restraints in Global Market
    Table 4. Key Players of Enterobacteriaceae Infection Drug in Global Market
    Table 5. Top Enterobacteriaceae Infection Drug Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Enterobacteriaceae Infection Drug Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Enterobacteriaceae Infection Drug Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Enterobacteriaceae Infection Drug Product Type
    Table 9. List of Global Tier 1 Enterobacteriaceae Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Enterobacteriaceae Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Enterobacteriaceae Infection Drug Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Enterobacteriaceae Infection Drug Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
    Table 30. Genentech Corporate Summary
    Table 31. Genentech Enterobacteriaceae Infection Drug Product Offerings
    Table 32. Genentech Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 33. Nanotherapeutics Corporate Summary
    Table 34. Nanotherapeutics Enterobacteriaceae Infection Drug Product Offerings
    Table 35. Nanotherapeutics Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 36. Novartis Corporate Summary
    Table 37. Novartis Enterobacteriaceae Infection Drug Product Offerings
    Table 38. Novartis Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 39. Pfizer Corporate Summary
    Table 40. Pfizer Enterobacteriaceae Infection Drug Product Offerings
    Table 41. Pfizer Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 42. Nymox Pharmaceutical Corporate Summary
    Table 43. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Product Offerings
    Table 44. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 45. Sequoia Sciences Corporate Summary
    Table 46. Sequoia Sciences Enterobacteriaceae Infection Drug Product Offerings
    Table 47. Sequoia Sciences Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 48. Phico Therapeutics Corporate Summary
    Table 49. Phico Therapeutics Enterobacteriaceae Infection Drug Product Offerings
    Table 50. Phico Therapeutics Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
    Table 51. Cantab Biopharmaceuticals Corporate Summary
    Table 52. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Product Offerings
    Table 53. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Enterobacteriaceae Infection Drug Segment by Type in 2021
    Figure 2. Enterobacteriaceae Infection Drug Segment by Application in 2021
    Figure 3. Global Enterobacteriaceae Infection Drug Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Enterobacteriaceae Infection Drug Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Enterobacteriaceae Infection Drug Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Enterobacteriaceae Infection Drug Revenue in 2021
    Figure 8. By Type - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 12. US Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 16. Germany Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 17. France Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 24. China Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 28. India Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 30. Brazil Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
    Figure 33. Turkey Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
    Figure 37. Genentech Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Nanotherapeutics Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Novartis Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Pfizer Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Sequoia Sciences Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Phico Therapeutics Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
60
Frequently Asked Questions
Enterobacteriaceae Infection Drug Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Enterobacteriaceae Infection Drug Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Enterobacteriaceae Infection Drug Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports